Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8481712B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 2, 2007 |
| Grant date | Jul 9, 2013 |
| Priority date | — |
| Expiry date | Feb 6, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.